Rapid Readouts: Initial Results of the Phase III BOSTON Study

Video

Related Videos
Krina K. Patel, MD, MSc
Olalekan O. Oluwole, MBBS, MD, associate professor, medicine, hematology/oncology, Vanderbilt Institute for Infection, Immunology and Inflammation, Vanderbilt University Medical Center
PAOLA-1: A Review of Progression-Free Survival and 5-Year Follow-up Overall Survival Analysis: Exploratory Post-Hoc Analysis by Clinical Risk of Relapse
Francesco Di Meo, PhD
Jay Spiegel, MD
Related Content
Samer A. Srour, MB ChB, MS

Early Responses With CTX130 Renew Hope for Anti-CD70 CAR T-Cell Therapy in Advanced RCC

April 29th 2024
Article
Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

October 10th 2022
Podcast
He Huang, MD, PhD, of First Affiliated Hospital, Zhejiang University School of Medicine

CD7 CAR T-Cell Therapy Plus Allogeneic HSCT Is Safe, Feasible in CD7+ Hematologic Malignancies

April 24th 2024
Article
FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL

FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL

July 28th 2022
Podcast
Saad Z. Usmani, MD, MBA, FACP, FASCO, of Memorial Sloan Kettering Cancer Center

Cilta-Cel Allows for Treatment-Free Period in Early R/R Multiple Myeloma

April 22nd 2024
Article
FDA

FDA Requires Boxed Warning for Risk of T-Cell Malignancies With Approved CAR T-Cell Therapies

April 19th 2024
Article